Quetmolimab: A Deep Dive into KANAb 001 and E-6011 Quest compound, KANAb 001, shows a promising treatment aimed at the PD-1 receptor. Initial clinical data from these studies, KANAb 001 and E-6011, demonstrate Quetmolimab anti-IL-17 antibody significant activity in multiple tumor forms. In particular, data point to a possible improvement in patien